there is no issue regarding SRX's ability to treat primary liver cancers.
there is no adverse implication on our ability to treat both the targeted cancers that we are seeking CE accreditation for.
still massively undervalued and sold by people who didn't bother to read the announcement. imo
there is no issue regarding SRX's ability to treat primary liver...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9286 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 412 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |